Fig. 5.

Effect of luminal perfusion of l-Glu/IMP or TGR5 agonists on HCO₃⁻ secretion and glucagon-like peptide-2 (GLP-2) release into portal vein (PV). A: total HCO₃⁻ output during the challenge period was calculated from Figs. 2–4. B: PV plasma concentration of GLP-2 was measured after 25-min perfusion of l-Glu (10 mM)/IMP (0.1 mM) and/or BTA (10 μM), or CCDC (10 μM). Each data point represents mean ± SE (n = 6 rats). *P < 0.05 vs. pH 7.0 Krebs group, †P < 0.05 vs. l-Glu + IMP group, ‡P < 0.05 vs. the corresponding TGR5 agonist group.